386 related articles for article (PubMed ID: 30244082)
1. Biosimilar medicines used for cancer therapy in Europe: a review.
Santos SB; Sousa Lobo JM; Silva AC
Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
[TBL] [Abstract][Full Text] [Related]
2. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
4. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
6. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
7. Rituximab biosimilars for lymphoma in Europe.
Jurczak W; Długosz Danecka M; Buske C
Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
[No Abstract] [Full Text] [Related]
8. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
9. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
[TBL] [Abstract][Full Text] [Related]
10. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M; Krendyukov A; Schiestl M; Gascón P
BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
[TBL] [Abstract][Full Text] [Related]
11. Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
Goldsmith D; Dellanna F; Schiestl M; Krendyukov A; Combe C
Clin Drug Investig; 2018 Jun; 38(6):481-490. PubMed ID: 29500617
[TBL] [Abstract][Full Text] [Related]
12. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
13. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
Mellstedt H
Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
[TBL] [Abstract][Full Text] [Related]
14. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
16. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
17. Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe.
Trollope R; Johnson S; Ireland H
Immunotherapy; 2017 Jun; 9(7):527-529. PubMed ID: 28523951
[TBL] [Abstract][Full Text] [Related]
18. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Thomas M; Thatcher N; Goldschmidt J; Ohe Y; McBride HJ; Hanes V
Immunotherapy; 2019 Oct; 11(15):1337-1351. PubMed ID: 31556762
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
20. Are Biosimilars the Future of Oncology and Haematology?
Zinzani PL; Dreyling M; Gradishar W; Andre M; Esteva FJ; Boulos S; González Barca E; Curigliano G
Drugs; 2019 Oct; 79(15):1609-1624. PubMed ID: 31541401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
